These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31356143)

  • 41. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.
    Kawashima I; Hudson SJ; Tsai V; Southwood S; Takesako K; Appella E; Sette A; Celis E
    Hum Immunol; 1998 Jan; 59(1):1-14. PubMed ID: 9544234
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy.
    Jakóbisiak M; Gołab J
    Arch Immunol Ther Exp (Warsz); 2010 Oct; 58(5):347-54. PubMed ID: 20694520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.
    Guo Y; Feng K; Liu Y; Wu Z; Dai H; Yang Q; Wang Y; Jia H; Han W
    Clin Cancer Res; 2018 Mar; 24(6):1277-1286. PubMed ID: 29138340
    [No Abstract]   [Full Text] [Related]  

  • 45. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
    Tomita Y; Imai K; Senju S; Irie A; Inoue M; Hayashida Y; Shiraishi K; Mori T; Daigo Y; Tsunoda T; Ito T; Nomori H; Nakamura Y; Kohrogi H; Nishimura Y
    Cancer Sci; 2011 Apr; 102(4):697-705. PubMed ID: 21231984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
    Tsimberidou AM; Guenther K; Andersson BS; Mendrzyk R; Alpert A; Wagner C; Nowak A; Aslan K; Satelli A; Richter F; Kuttruff-Coqui S; Schoor O; Fritsche J; Coughlin Z; Mohamed AS; Sieger K; Norris B; Ort R; Beck J; Vo HH; Hoffgaard F; Ruh M; Backert L; Wistuba II; Fuhrmann D; Ibrahim NK; Morris VK; Kee BK; Halperin DM; Nogueras-Gonzalez GM; Kebriaei P; Shpall EJ; Vining D; Hwu P; Singh H; Reinhardt C; Britten CM; Hilf N; Weinschenk T; Maurer D; Walter S
    Cancer Immunol Res; 2023 Jul; 11(7):925-945. PubMed ID: 37172100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Yee C; Thompson JA; Byrd D; Riddell SR; Roche P; Celis E; Greenberg PD
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16168-73. PubMed ID: 12427970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice.
    Schmidt K; Keller C; Kühl AA; Textor A; Seifert U; Blankenstein T; Willimsky G; Kloetzel PM
    Cancer Res; 2018 Jun; 78(12):3243-3254. PubMed ID: 29559473
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
    Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
    J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
    Chmielewski M; Kopecky C; Hombach AA; Abken H
    Cancer Res; 2011 Sep; 71(17):5697-706. PubMed ID: 21742772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
    Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
    J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.
    Akazawa Y; Hosono A; Yoshikawa T; Kaneda H; Nitani C; Hara J; Kinoshita Y; Kohashi K; Manabe A; Fukutani M; Wakabayashi M; Sato A; Shoda K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
    Cancer Sci; 2019 Dec; 110(12):3650-3662. PubMed ID: 31571332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
    Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
    J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.
    Ando M; Nakauchi H
    Exp Hematol; 2017 Mar; 47():2-12. PubMed ID: 27826124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.